Viruses, as a class of pathogenic microbe, remain a significant health burden globally. Viral infections result in significant morbidity and mortality annually and many remain in need of novel vaccine and anti-viral strategies. The development of effective novel anti-viral therapeutics, in particular, requires detailed understanding of the mechanism of viral infection, and the host response, including the innate and adaptive arms of the immune system. In recent years, the role of glycans and lectins in pathogen-host interactions has become an increasingly relevant issue. This review focuses on the interactions between a specific lectin family, galectins, and the broad range of viral infections in which they play a role. Discussed are the diverse activities that galectins play in interacting directly with virions or the cells they infect, to promote or inhibit viral infection. In addition we describe how galectin expression is regulated both transcriptionally and post-transcriptionally by viral infections. We also compare the contribution of known galectin-mediated immune modulation, across a range of innate and adaptive immune anti-viral responses, to the outcome of viral infections.
INTRODUCTION
Viruses are a ubiquitous class of microbe that have coevolved with the hosts they infect over millions or years. In humans, and many other animals, viruses remain a significant health burden. The development of novel vaccines and anti-viral therapeutics is informed by understanding of host-virus interactions, including interactions between virions and the cells they infect, cellular responses to infection, and innate and adaptive immune cell responses. In recent years, the role of glycan-lectin interactions in shaping hostmicrobe interaction has become increasingly appreciated. The focus of this review is the lectin family, galectins and the diverse roles that these glycan-binding proteins play in a range of viral infections. Specifically, the broad activity of galectins in regulating the immune response to viral infection and how viral infection can control galectin expression, in addition to the direct effects of galectins on initial viral infection and replication, are discussed.
To date, 15 mammalian galectins have been identified. Evolutionarily, galectins are also conserved in many phyla, including birds, amphibians, fish, nematodea, drosophila, sponges and fungi [1] . Galectins are defined by the presence of a highly conserved~130 amino acid carbohydrate recognition domain (CRD) that recognizes b-galactosides [2, 3] . This saccharide structure is commonly found in N-linked (complex-type) glycans and O-linked glycans. Despite the highly conserved nature of galectin CRDs, subtle yet significant differences occur in the binding affinity between different members of the galectin protein family.
Galectins can be sub-divided into three groups defined by structural differences in the CRD arrangement (Fig. 1) . Prototype galectins (Gal-1, 2, 5, 7, 10, 13, 14 and 15) exist as monomers, with some (Gal-1, 2, 11, 13, 14 and 15) able to associate into homodimers. Tandem repeat-type galectins (Gal-4, 6, 8, 9 and 12) have two distinct CRDs connected by a flexible peptide linker. Gal-3 is uniquely a chimera-type galectin, possessing one CRD and a non-lectin domain. Gal-3 can oligomerize via its non-lectin domain to form higher order structures [4, 5] . Importantly, the multivalency of galectins allows these proteins to bind multiple glycan ligands on the same cell, on opposing cells, or with the extracellular matrix, or to crosslink microbes and host cells [6] [7] [8] .
Galectins are synthesized in the cytosol on free ribosomes and accumulate in the cytoplasm of cells [9, 10] . Secretion of galectins into the extracellular milieu occurs via a poorly characterized pathway, termed non-classical or leaderless secretion [11] . This involves the accumulation of galectins at the cytoplasmic side of the plasma membrane and release in vesicles or exosomes, or direct translocation across the plasma membrane [12, 13] . Galectins are stored in the cytoplasm of many types of immune and stromal cells that occur at the entry sites of pathogenic micro-organisms, including fibroblasts, keratinocytes, endothelial cells and mucosal membrane epithelial cells [14] . Galectin-1, -3, -9 and -12 are commonly found in cells involved in immune responses [15, 16] . Many immune cells express galectins upon differentiation or activation by receptor engagement or cytokine stimulation [17] , and the cells may release them in response to infection, either passively by dying cells or actively through secretion via a non-classical pathway [18] . This review focuses on galectins as a family of lectins that have broad activity in the modulation of human infections across a range of RNA and DNA viruses. Glycans and lectins play significant and diverse roles in viral biology and shape hostvirus interactions, from initiation of infection, pathogen sensing, to shaping the innate and adaptive immune response. Galectins are increasingly described as mediators of pathogen recognition and sensing, but their ability to interact with both pathogen and human glycans means that the role of galectins in viral infections is complex and diverse.
Galectins can interact directly with viruses to modulate infection
Many viruses rely on glycan-lectin interactions to initiate viral infection. In particular, a range of viruses utilize virally encoded glycoproteins [e.g. human immunodeficiency virus (HIV), nipah virus, herpes simplex virus (HSV), human Tcell lymphotropic virus (HTLV), dengue virus and influenza virus] to facilitate attachment and entry. Therefore it is unsurprising that galectin family members have the ability to regulate such activity given their well-characterized role as lectins with the potential to interact directly with viral glycoproteins and/or glycosylated viral entry receptors. Direct recognition of microbial pathogens by galectins is a property shared with other lectin types. such as C-and Flectins, ficolins and pentraxins [19] . Due to the multimeric structures galectins form, they can crosslink glycans and promote viral-host cell interactions. Within the galectin family of lectins, Gal-1, Gal-3 and Gal-9 form the archetypal galectins within each structural subclass, prototype, chimeric-type and tandem repeat-type, respectively. These three galectins have been studied extensively and are the major galectin family members identified to date that regulate viral infection. This regulation of infection occurs across a diverse range of viral families, including both DNA and RNA viruses that are either enveloped or non-enveloped, with modulation of infection characterized in a range of in vitro and in vivo models (Fig. 2) . The outcome of interactions between galectins can enhance or inhibit infection and this depends on the type of galectin, its concentration and the specific cell surface or extracellular microenvironment. These factors will be discussed in the following sections.
HIV and Gal-1
The retrovirus HIV remains a significant heath burden today [20] . A substantial proportion of the global population is infected with HIV and despite advances in combination anti-retroviral therapies, infection still often results in acquired immunodeficiency syndrome (AIDS) [21] . Extensive investigations of the modulation of infection of human immunodeficiency virus type 1 (HIV-1) by galectins have reported that Gal-1, Gal-3 and Gal-9 can enhance and/or inhibit aspects of infection. Gal-1, for example, can enhance viral adsorption and/or fusion with target cells to promote the initiation of infection, but conversely can induce apoptosis of latently infected T cells to limit the available latent pool [22] [23] [24] [25] . Treatment of T cells with Gal-1 prior to infection resulted in a dose-dependent increase in HIV-1 infectivity [22] . This enhancement of infection was specific to Gal-1 and did not occur with Gal-3. Furthermore, enhanced infection was dependent on the lectin activity of Gal-1, as it could be blocked by the addition of lactose, a known competitive inhibitor of CRD-dependent binding. The Gal-1-mediated increase in HIV-1 infectivity was due to accelerated kinetics of HIV-1 attachment but not fusion. The consequence was enhanced resistance to monoclonal antibody neutralization and chemokine treatments [22] . Gal-1 enhanced adsorption by crosslinking the viral glycoprotein gp120 to its cellular glycoprotein receptor CD4 to promote viral attachment to target cells [23] .
Further in vitro studies established that Gal-1, but not Gal-3, also enhanced infection of macrophages, a cell type encountered early in HIV-1 infection [24] . As attachment is a major limiting factor in HIV infection [26] , increases in the rate of attachment could facilitate the establishment of HIV infection in patients.
Both CD43 and CD45 are cell surface receptors for Gal-1 and have been associated with T cell susceptibility to Gal-1-induced cell death [27] [28] [29] . The initial observation that CD43 and CD45 have altered glycosylation patterns during HIV-1 infection prompted the investigation of Gal-1 activity in modulating T cells infected with HIV-1 [25] . Gal-1 bound to and induced cell death more readily in latently infected compared to productively infected T central effector member cells (T CEM ) [25] . Thus, the glycosylation changes correlated with increased susceptibility to Gal-1-induced cell death, and led to a reduction in the latently infected T cell pool. Gal-1 therefore differentially regulates HIV-1 infection at different stages of viral infection. While Gal-1 interacts with HIV-1 virions directly in vitro [22, 24, 30] , whether Gal-1 regulates HIV-1 infection in vivo needs to be further evaluated. Despite this uncertainty, ongoing research is seeking to identify Gal-1 inhibitors as a novel means of treating HIV-1 infection [31] . There is significant Fig. 2 . Galectins can interact directly with viruses and/or target cells to promote or inhibit infection. Schematic summary of Gal-1 (purple), Gal-3 (orange) and Gal-9 (green) host-virus interactions that result in the promotionor inhibition of infection by RNA and DNA viruses.
interest in the role of Gal-1 in the establishment of HIV-1 infection and latency, and this underscores the importance of clearly defining how and when Gal-1 mediates anti-viral activity during HIV-1 infections.
HIV and Gal-3
Studies examining the role of Gal-1 in directly modulating HIV-1 infection used Gal-3 as a control to demonstrate that Gal-1-mediated regulation was not a general property of galectins. Exogenous treatment with Gal-3 had no effect on the initiation of HIV-1 infection of T cells [22] or macrophages [24] . Interestingly, Gal-3 was able to enhance the release kinetics of HIV-1 [32] , acting by interacting intracellularly with the HIV-1 protein Gag and the cellular protein, Alix, which are essential for viral budding during the production of new infectious virions [32] . Gal-3 was shown to crosslink Alix and Gag, resulting in stabilization of this interaction, and incorporation of Gal-3 into newly formed virions [32] . Furthermore, Gal-3 that had been incorporated into exosomes derived from HIV-1-infected cells was able to enhance the spread of infection [33] . HIV-1-infected dendritic cells (DCs) had increased total cellular Gal-3, with a concomitant increase in exosome-associated Gal-3. Exosomes derived from HIV-1-infected DCs can transfer infection to uninfected T cells, and facilitate replication through fibronectin-and Gal-3-mediated cellular fusion [33] . Exosomes derived from infected DCs were more efficient at transferring infection to T cells than cell-free HIV-1 virions and the addition of b-lactose during the infection of T cells with DC-derived exosomes resulted in significantly reduced viral transmission [33] . Thus, Gal-3 modulation of HIV-1 infection is dependent on intracellular expression of Gal-3, resulting in enhanced release of infectious progeny and/or exosome-mediated infection of target cells.
Gal-3 can also function in an anti-viral manner during HIV-1 infection. Similar to Gal-1, Gal-3 acts in an anti-viral manner by inducing apoptosis of infected cells to limit viral infection. Treatment of HIV-1-infected monocyte-derived macrophages with Gal-3 resulted in significantly increased cell death of infected cells compared to uninfected cells in a caspase-independent fashion [34] . The induction of cell death during viral infection is an intrinsic cellular defence resulting in the disruption of viral progeny production, with multiple galectin family members playing a role in this control via the regulation of apoptosis [35] .
HIV and Gal-9 Gal-9 also possesses the ability to enhance or inhibit HIV-1 infection in a manner that is dependent on the cell surface expression of both viral entry receptors and host molecules that interact with Gal-9. Gal-9 interacts with T cells via its receptor T cell immunoglobulin and mucin-domain containing-3 (Tim-3), which in turn can regulate HIV-1 infection [36] . Treatment of activated CD4 + T cells with Gal-9 prior to infection significantly decreased HIV-1 infection, in a Tim-3-dependent manner [36] . Pre-treatment with Gal-9 inhibited infection through the downregulation of multiple HIV-1 receptors, including CCR5, CCR4 and a4-b7 integrin [36] . In addition, Gal-9 also restricted HIV-1 viral replication in CD4 + T cells that were already infected with HIV-1. Gal-9 treatment also inhibits HIV-1 infection of monocytes [36] .
Protein disulfide isomerase (PDI) was identified as a novel Gal-9 receptor found on the plasma membrane [37] . Gal-9 specifically retained PDI on the surface of resting T cells, in a CRD-dependent manner. PDI changes the redox state at the cell membrane, leading to a more favourable environment for HIV-1 entry [38] [39] [40] , and thus Gal-9-mediated accumulation of PDI increases HIV-1 infection of T CEM cells [37] . This PDI-dependent activity on HIV-1 infection was confirmed by Elahi et al., who also demonstrated the inhibitory activity of Gal-9 on activated T-cells [36] . This established that the effect of Gal-9 on HIV-1 infection is dependent on the receptor(s) with which it interacts, which are in turn influenced by the activation status of the cells. Resting CD4
+ T cells treated with Gal-9 showed increased HIV-1 infection via its interaction with PDI, while activated CD4 + T cells showed reduced infection following Gal-9 treatment, resulting from interactions with Tim-3. Additionally, the presence of Gal-9 in the plasma of HIV-1-infected individuals correlated with viral replication, indicating a possible role for Gal-9 in the pathogenesis of HIV-1 [36, [41] [42] [43] [44] ].
An additional post-entry effect of Gal-9 on HIV-1 was identified using T cells latently infected with HIV-1. Gal-9 treatment of latently infected CD4 + T cells isolated from individuals on suppressive anti-retroviral therapy demonstrated that Gal-9 enhanced HIV-1 reactivation [45] . This reversal of latency was not dependent on any known Gal-9 receptors on T cells such as Tim-3, PDI and CD44. Furthermore, Gal-9 activity was not blocked by lactose, and thus was independent of lectin activity. Analysis of gene expression during Gal-9 treatment of latently infect cells determined a bi-directional regulation of HIV-1 transcription [45] . Recombinant Gal-9 induced the expression of several pro-viral transcription initiation factors, thus promoting reactivation and viral gene transcription. Conversely, Gal-9 modulated the expression of anti-HIV host restriction factors associated with cellular intrinsic immune defence, including the innate anti-viral factor APOBEC3G, which is incorporated into virions and drives hyper-mutation of the viral genome, frequently resulting in the production of nonviable viral progeny [45] . Upregulation of APOBEC3G during recombinant Gal-9 treatment corresponded with a significant reduction in the infectivity of viral progeny [45] . Taken together, the study of HIV-1 infection regulation by Gal-9 demonstrated that Gal-9 can have vastly different activities depending on the receptors with which they interact, the activation status of the cells and the point in the viral infectious lifecycle.
HTLV and Gal-1 HTLV is also a member of the retrovirus family. This virus infects approximately 20 million people globally and is associated with serious disease, including adult T cell leukaemia [46, 47] . Gal-1 was found to stabilize the attachment of human T-cell lymphotropic virus type 1 (HTLV-1) to human T cells, as described for HIV. Gal-1 treatment resulted in a CRD-dependent increase in infectivity, as well as increased fusion of HTLV-1-infected cells [48] . Additionally, latently infected T cell lines have increased expression and secretion of Gal-1, suggesting that manipulating this could promote virus infection [48] .
Nipah virus and Gal-1 Nipah virus is a highly pathogenic member of the family Paramyxoviridae. Nipah virus causes a severe encephalitic syndrome with high associated mortality rates [49] . Studies into the effects of Gal-1 on Nipah virus infection have demonstrated the significance of the timing of galectin treatment during viral infection. During Nipah virus infection in vivo, the formation of syncytia is important for pathogenesis as well as cell-to-cell spread of viral infection [50] . Initial studies identified and characterized a mechanism by which Gal-1 could inhibit Nipah virus infection through the inhibition of syncytia formation. The formation of syncytia is reliant on two viral glycoproteins, NiV-F and NiV-G, which, when expressed on the cell surface, induce the fusion of adjoining cell membranes [51] . The addition of Gal-1 was sufficient to inhibit syncytia formation in vitro in a number of cell lines expressing NiV-F and NiV-G [51] . This Gal-1-mediated inhibition was abrogated by the addition of a Gal-1 blocking antibody or lactose, indicating that it is specific to the CRD of Gal-1. Furthermore, Gal-1 inhibited membrane fusion induced by other members of the family Paramyxoviridae, including Hendra and human parainfluenza virus type III. However, two retroviruses, human T-cell lymphotrophic virus II and murine leukaemia virus and the pox virus, vaccinia were not inhibited [51] . The inhibitory effect of Gal-1 did not occur when monomeric Gal-1 was added and thus was reliant on the multimeric form of Gal-1. Gal-1 inhibited NiV-F in three distinct ways: retention of NiV-F in its immature form, reduced lateral movement of NiV-F on the plasma membrane and direct inhibition of the fusogenic activity of NiV-F [52] . Finally, Gal-1 was also associated with reduced viral budding from infected endothelial cells [52] . Taken together, these findings demonstrate that when Gal-1 is present late in the replication cycle of Nipah virus, it inhibits viral release and cell-to-cell spread.
Conversely, the same group showed that Gal-1 subsequently increased Nipah virus cell-free infection of target cells, in a manner that was also CRD-dependent [53] . The entry of Nipah virus requires two steps: viral attachment to the surface of the target cells and then fusion of the virion envelope with the cell membrane, mediated by NiV-F. Dissecting the effect of Gal-1 on viral attachment and fusion using temperature shift experiments demonstrated that the presence of Gal-1 during the attachment stage resulted in increased viral entry, while Gal-1 that was present at the fusion stage had no effect on viral entry [53] . Interactions with glycans on both the cell surface and viral envelope were important for Gal-1-mediated inhibition of Nipah virus entry. These observations reinforce the concept that one galectin can have pro-viral or anti-viral effects during the infection of a specific virus, depending on the timing and context of galectin binding to viral/host glycoproteins.
HSV and Gal-3
Herpes simplex virus type 1 (HSV-1) is a ubiquitous human pathogen of the family Herpesviridae. Up to 70 % of the human population is infected with HSV-1, and furthermore, HSV-1 persists as a lifelong latent infection in neuronal cells [54] . Gal-3 can interact directly with HSV-1 virions to promote infection. Analysis via affinity chromatography determined that HSV-1 virions could bind to immobilized Gal-3 [55, 56] . The functional role of this interaction was investigated during HSV-1 infection of keratinocytes, a cell type of clinical significance that in vivo is exposed to Gal-3 found in the human cornea [55] . When Gal-3 was knocked down in human corneal keratinocytes by small interfering RNA, infection was significantly reduced, with an associated reduction in plaque number and size [55] . When Gal-3 was blocked using Gal-3-binding mucins (MUC16) derived from corneal keratinocytes, HSV-1 infectivity was decreased [55] . Thus Gal-3 has been identified as a mediator of HSV-1 entry during ocular infection. It remains to be determined whether this association holds true for HSV-1 entry at other sites on infection; mucosa and neuronal cells are of key clinical interest.
Influenza virus and Gal-1 Influenza belongs to the family Orthomyxoviridae, and is associated with seasonal and pandemic outbreaks. The surface viral glycoproteins of influenza virus A (IAV), haemagglutinin and neuraminidase, both have potential galectinbinding N-linked oligosaccharide chains and so galectins are expected to regulate IAV infection. In fact, Gal-1 can inhibit IAV infection both in vitro and in an in vivo murine model [57] . Overexpression of endogenous Gal-1 in target cells, and treatment of target cells with exogenous Gal-1, resulted in the inhibition of IAV replication in vitro [57] . In addition, Gal-1 expression was increased in airway epithelia during the infection of mice with IAV. Intranasal therapy with Gal-1 reduced weight loss and enhanced survival in mice infected with a lethal dose of IAV compared to untreated mice [57] . Additionally, Gal-1 knockout mice had lower survival rates following infection compared to wildtype mice, with an associated decrease in viral yields from bronchoalveolar lavage and reduced histopathology in the lungs of Gal-1-treated mice [57] . This study demonstrated that Gal-1 can bind directly to diverse IAV subtypes, including H1N1, H2N2, H3N2, H5N2 and H6N1, indicating that Gal-1 could be inhibiting the initiation of infection. This is consistent with the general principle that soluble lectins are associated with protection against viral infection [7] . In the human setting, a genome-wide association study involving IAV (H7N9)-infected patients revealed that polymorphisms in the LGALS1 gene, which encodes Gal-1, were associated with susceptibility to infection [58] . Patients expressing genetic variants that resulted in higher levels of Gal-1 mRNA and protein had increased protection from IAV H7N9 infection [58] , mirroring the data from murine models indicating a protective role for Gal-1 in influenza infection.
Influenza virus and Gal-3 and Gal-9 Gal-3 has been also demonstrated to inhibit IAV infection. Exogenous treatment with Gal-3 during IAV infection in vitro resulted in reduced cytopathic effect and virus yield [59] . This inhibition was associated with Gal-3-induced upregulation of anti-viral genes, including IFN-b, IFN-g, PKR and 2¢,5¢-oligoadenylate synthetase (OAS) in infected cells. This supports the finding that Gal-3 has cytokine-like functions via signalling though the JAK-STAT pathway [60] and therefore could be a component of the innate immune response to IAV infection.
IAV infection is also abrogated by Gal-9. Transgenic mice engineered to overexpress Gal-9 had higher survival rates than control mice following virus challenge [61] . The antiviral activity of Gal-9 was confirmed in vitro. Gal-9 bound to H1N1 and H3N2 strains of IAV, resulting in reduced infection as assessed by plaque assay [61] . Interestingly, in this experimental system, Gal-1 and Gal-3 failed to reduce IAV infection. The studies discussed above used IAV viral stocks that were produced from different cell lines, and it has been suggested that stocks produced from different cells lines result in differential glycosylation of viral glycoproteins [57] [58] [59] [60] [61] .
Dengue virus and Gal-1 Dengue virus infection presents another major health threat globally; over 50 % of the global population live in areas at risk of infection by this flavivirus [62] . Gal-1 has also been identified as an inhibitor of dengue virus serotype 1 (DENV-1) infection. Gal-1 can interact with cell surface glycoproteins on DENV-1-permissive cell lines, including a carcinoma cell line with endothelial characteristics (ECV-304), and lung microvascular endothelial cells (HMVEC-L) [63] . Exogenous treatment of target cells with Gal-1 prior to DENV-1 infection resulted in a significant decrease in initial infection, with a corresponding decrease in the release of viral progeny [63] . This inhibitory effect was specific to Gal-1, was not recapitulated by Gal-3 and was dependent on multimeric Gal-1-binding in a CRD-dependent manner. Gal-1 was also shown to interact with the DENV-1 virions but pre-treatment of target cells with Gal-1 lead to greater inhibition compared to pre-treatment of DENV-1 virions, although both showed a significant reduction in viral loads in the supernatant. Gal-1 was able to inhibit both viral adsorption and internalization but was not virucidal. Furthermore, Gal-1-deficient mice infected with DENV-1 succumbed to infection earlier than wild-type mice [63] . This suggests that Gal-1 treatment results in the blocking of dengue virus infection, with Gal-1-mediated inhibition being reliant on the bridging of both cellular and viral glycans.
Enteroviruses and Gal-1 and Gal-3
During infection with enterovirus (EV), a member of the family Picornaviridae, Gal-1 was demonstrated to interact with EV71 virions via the viral capsid proteins (VP1 and VP3) [64] . Virus propagated in cell lines stably expressing lentivirus-based shRNA to knockdown Gal-1 had reduced Gal-1 associated with viral progeny, as determined by immunoprecipitation. This Gal-1-low virus had reduced infectivity, which could be recovered by the addition of exogenous Gal-1. Furthermore, Gal-1-associated virions had increased long-term stability [64] . Similarly, Gal-3 is associated with EV infection, as infection of Gal-3 knockout cells resulted in a significant decrease in viral titres late in infection [65] . It was identified that when Gal-3 was knocked down there was increased cell survival early in infection, but reduced apoptosis later in infection. The paper suggests that Gal-3 modulates EV release through the regulation of apoptosis. Thus, two galectins, Gal-1 and Gal-3, both promote EV infection through different mechanisms; Gal-1 enhances the initiation of infection, while Gal-3 enhances the release of viral progeny.
Human cytomegalovirus (HCMV) and Gal-9 HCMV is a ubiquitous human herpesvirus that can cause significant morbidity and mortality, in particular where host immunity is compromized or underdeveloped [66] . We have recently identified that Gal-9 can potently inhibit the infection of multiple HCMV strains in both human fibroblasts and epithelial cells; however, Gal-1 is not capable of such inhibitory activity [67] . The ability of Gal-9 to inhibit HCMV infection is dependent on the lectin activity of the protein and through the use of temperature shift assays it was determined that Gal-9 exhibits its function during viral entry, leading to a potent inhibition of HCMV infection.
Although we have focused here on galectin-mediated regulation of human viral infections, it is interesting to note that galectins are found in all invertebrates [1] . Indeed, galectins can have anti-viral activity in non-mammalian species, e.g. the prototype galectin-1 (Drgal1-L2) and prototype galectin-3 (Drgal3-L1) encoded by zebrafish bind to and inhibit infection of the rhabdovirus, infectious haematopoietic necrosis virus [68] , suggesting that the anti-viral activity of galectins is an evolutionarily conserved function of this family.
Viruses regulate galectin expression during infection
In addition to the virus-galectin interactions described above, a range of viruses regulate galectin expression during infection ( Table 1 ). Viruses that regulate galectins are discussed below. To date, Gal-1, Gal-3 and Gal-9 remain the only galectins reported to be regulated during viral infections.
Gal-1
Study of Gal-1 regulation during viral infections has predominantly focused on whether transcription is regulated by viral infection. During infection with pandemic (2009A H1N1) but not seasonal IAV (H1N1) [69] , and in AIDSrelated Kaposi's sarcoma (KS) skin lesions, Gal-1 mRNA levels were upregulated [70, 71] . Gal-1 gene transcripts were also elevated in HTLV chronically infected T cells with the viral protein, Tax, which is capable of upregulating Gal-1 expression in an NK-kB-dependent manner [48] . Additionally, EBV latently infected B cell lines had increased Gal-1 transcription and cellular protein expression [72, 73] , with upregulation of Gal-1 detected in Reed-Sternberg cells Machala et al., Journal of General Virology regulated by the AP-1 transcription factor. HSV-1 infection in vitro also resulted in a potent upregulation of Gal-1 protein expression and secretion [74] . There are potentially multiple factors driving Gal-1 expression in KS, as in vitro KSHV infection of human dermal microvascular endothelial cells resulted in the downregulation in Gal-1 expression during infection [75] . Given the extensive roles of Gal-1 in immune regulation, the potential role of elevated Gal-1 expression from virally infected cells in immune effector responses is worthy of further study.
Gal-3
Gal-3 is often upregulated in viral infections. For example, HIV-1 infection increased Gal-3 transcription and translation during in vitro infection of T cell lines [76] . Similarly, in vitro infection of T cell lines with HTLV (HTLV-1) led to increased Gal-3 expression and then enhanced secretion [77] . Both HIV-1-and HTLV-mediated upregulation of Gal-3 was dependent on the expression of the viral proteins Tat and Tax, respectively [77, 78] . Intriguingly, in vitro infection of keratinocytes (HaCaT) and epithelial (ARPE-19) cells with HSV-1 resulted in an increase in Gal-3 carbohydrate-binding activity and secretion despite there being no increase in Gal-3 gene expression early in HSV-1 infection [56] . In comparison, Gal-3 mRNA and total protein expression was decreased in KSHV-related tumours (latency gene expressing, LANA-positive) and in human dermal microvascular endothelial cells infected with body cavitybased lymphoma (BCBL)-1 virus to model KSHV infection in vitro [75] . The infection of a different endothelial cell line (HUVEC) with KSHV not did result in a significant increase in Gal-3 gene expression, which could mean that Gal-3 regulation during KSHV infection can differ between different endothelial cell populations [75] .
Viral infections associated with inflammatory cell infiltration were shown to have increased Gal-3 plasma levels. IAV (H5N1) infection resulted in increased expression of Gal-3 mRNA and protein in the lungs of infected mice [79] . Further investigation of lung sections by immunohistochemical analysis showed that the source of Gal-3 was infiltrating cells rather than lung epithelial cells [79] . In hepatitis C (HCV)-associated cirrhosis, plasma Gal-3 was elevated but was mostly associated with cirrhosis rather than viral infection [80] . Similarly, cirrhotic liver and hepatocellular carcinoma patients had elevated plasma Gal-3, which was not strictly associated with hepatitis B (HBV) infection [81] . Chronically HBV-infected individuals had increased Gal-3 in serum compared to both inactive HBV carriers (HBV seropositive with DNA levels <2000 IU ml À1 and no liver damage) and healthy controls [82] . Additionally, in a HSV-1 infection murine model of herpetic allodynia, Gal-3 expression was increased in the spinal dorsal horn following HSV-1 infection, with the corresponding increased protein expression being confirmed by Western blot [83] . Additionally, murine infection with encephalomyocarditis virus induced Gal-3 protein expression in micro-lesions within the cerebellum of infected mice [84] . Similarly, in a mouse model of argentine haemorrhagic fever associated with Junin virus infection, Gal-3 gene expression was upregulated and protein expression confirmed [85] . It remains unclear what is driving Gal-3 upregulation in the majority of these viral infections, although the determination that Gal-3 upregulation can be dependent on the expression of viral proteins Tat (from HIV-1) and Tax (from HTLV) [77, 78] indicates that viral gene expression could at least in part be driving Gal-3 expression.
Gal-9
Gal-9 was first identified as a tumor-associated antigen that is upregulated in the spleen of a patient with EBV-associated Hodgkin's disease [86] . Gal-9 was identified as one of eight genes that were upregulated during DENV infection [87] , with Gal-9 plasma concentrations being increased in patients with acute DENV infection, and Gal-9 concentrations being associated with disease severity [88] . In vitro DENV infection of macrophages resulted in the upregulation of Gal-9 mRNA, but not Gal-1 or Gal-3 [89] . This specificity of Gal-9 regulation was confirmed in patients with acute DENV infection who had elevated plasma Gal-9 concentrations but no change in Gal-1 and Gal-3 compared to healthy controls [90] .
A number of viral infections result in systematic upregulation of Gal-9 in patient plasma during productive viral infection, with a concomitant reduction in Gal-9 following resolution or treatment of infection. A murine model of IAV infection established that Gal-9 protein levels were increased in the lungs of infected mice [91] . Gal-9 concentrations in the serum of IAV patients was significantly higher than in both pneumococcal pneumonia patients and healthy controls and decreased after treatment with antiinfluenza drugs [92] . A number of studies have also demonstrated increased Gal-9 in the plasma of patients with active HIV-1 infection that returned to near-normal levels following anti-viral treatment [36, [41] [42] [43] . Furthermore, Gal-9 protein was higher in plasma during periods of detectable viraemia in HIV-1-positive individuals compared to HIVuninfected controls [44] . In chronically infected HBV but not HCV patients there was an increase in circulating Gal-9 that correlated with disease severity [93, 94] . Furthermore, infected cells provided a source of Gal-9 in a number of other viral infections, including HCMV [95] , HCV [96] , latent EBV infection [97] and neuronal HSV-1 infection [98] , yet the mechanisms responsible for such increases are yet to be identified.
The trend of systemic upregulation of Gal-9 during viral replication suggests that viral replication or an acute response to viral replication drives Gal-9 expression. Clinical infection with HCMV results in primary infection followed by lifelong latency and the potential to reactivate to yield newly replicating virus [66] . Peripheral blood mononuclear cells (PBMCs) isolated from patients experiencing HCMV reactivation in the post-haematopoietic transplant setting had elevated Gal-9 mRNA expression [95] . More recently Machala et al. extended this observation and demonstrated the upregulation of serum Gal-9 protein levels in haematopoietic stem cell transplant recipients at the peak of clinical HCMV reactivation, but not in matched transplant recipients without reactivation [67] . The antiviral cytokine IFN-b mediates Gal-9 upregulation during HCMV infection in vitro [95] . A recent study identified Gal-9 as a core interferon-stimulated gene (ISG), i.e. it was upregulated in response to type I interferons (IFNs) in all mammalian species tested [99] . This conservation suggests an important role for Gal-9 in mediating the mammalian response to IFNs. Interestingly, no other galectin was identified as a core ISG or demonstrated to be regulated by IFN signalling. Given the critical role of type I and type II IFNs in controlling viral infections, it is tempting to speculate that these molecules may be key drivers of Gal-9 upregulation across a number of viral infections where higher Gal-9 levels have been reported, including IAV, HBV, HIV-1 and DENV infections [36, 41-43, 87-91, 93] . However, it is important to note that the precise molecular mechanisms controlling such cytokine-mediated regulation of galectin expression during viral infection remain to be fully elucidated.
In addition, Gal-9 is upregulated by a number of immune mediators in response to viral infection. During primary HIV-1 infection, Gal-9 could be detected in the serum as early as 5 days after the first detection of HIV RNA and tracked circulating levels of other cytokines, including IL-10, tumour necrosis factor and IL-1b. [44] . In addition, Gal-9 expression is upregulated on the surface of CD4 + T cells during chronic HIV-1 infection [100] . Similarly, Gal-9 expression was increased in CD4 + T cells from HAVinfected paediatric patients compared to healthy children [101] . Innate immune cells are also a source of Gal-9 in viral infection. For example, infiltrating macrophages express Gal-9 during HSV-1 infection [98] . In HCV infection, IFNg (but not IL-1b, LSP or HCV core protein) is a potent inducer of Gal-9 in monocytes and macrophages [102] . In another model, CD14
+ monocytes upregulated Gal-9 upon recognition of HCV-infected hepatocytes [103] . Furthermore, Kupffer cells in the lungs [102] , regulatory T cells (Tregs, CD39 + ) in circulation [104] , and CD14 + and CD11 + monocytes in the liver and spleen all upregulate Gal-9 during HCV infection [105] . Similarly, in HBV-associated hepatocellular carcinoma tissue, Kupffer cells expressed high levels of Gal-9 protein, which was induced by IFN-g secreted by infiltrating T cells [93, 106] . Myeloid DCs and plasmacytoid DCs also served as a source of Gal-9 in HBVinfected patients [106] . Taken together, these results indicate that Gal-9 can be expressed and secreted by a number of innate and adaptive immune cells during viral infection.
Galectins modulate anti-viral immune responses
In addition to the regulation of galectins by viral infection, galectins are abundantly expressed by innate and adaptive immune cells, either constitutively or in an inducible manner. Frequently, galectin expression is upregulated during the activation of immune cells, including B cells, T cells, natural killer (NK) cells, inflammatory macrophages and Tregs [107] . Furthermore, galectins are involved in regulating a large array of immune processes, including the regulation of the migration of neutrophils, monocytes and DCs [108, 109] , cytokine secretion and signalling [15, 110] , and T and B cell death [35, 111, 112] .
Impact of galectins on T cells during virus infection
Gal-1 is known to be associated with inducing the apoptosis of activated T cells [27] . As T cells are potent anti-viral effectors that play a key role in the control of infection, Gal-1 regulation of T cells is a topic of interest. However, although a broad range of viruses upregulate Gal-1 during infection, studies focusing on the relevance of Gal-1 in viral pathogenesis have only been undertaken for two viruses, both members of the family Herpesviridae: Epstein-Barr Virus (EBV) and HSV.
Cytotoxic T lymphocytes (CTLs) are key effector cells for the efficient control of both the acute and chronic stages of most viral infections. The discovery that Gal-1 was upregulated in Hodgkin's lymphoma (HL) prompted an examination of Gal-1-mediated regulation of CTLs during EBV infection. EBV-specific CD8 + T cells from patients with high Gal-1 expression in Hodgkin/Reed-Sternberg cells showed selective loss of IFN-g expression in T cells specific for the latency-associated epitopes (LMP1/2) [72] . Additionally, EBV-specific CD8 + T cells stimulated with epitopes of the latency-associated EBV proteins LMP1/2 and EBNA1 had reduced proliferation following treatment with Gal-1 [113] . Interestingly, Gal-1 did not affect IFN-g production or the proliferation of CD8 + T cells directed toward epitopes derived from EBNA3-6 and lytic antigens [72, 113] . This suggests that Gal-1 can specifically target T cells of differing specificities to shape the immune response to different stages of viral infection.
Recent studies have identified that polyfunctional T cells that have the capacity to produce multiple cytokines (IFNg, TNF) and chemokines, and to rapidly degranulate (CD107a), are critical for antiviral protective immunity [114] [115] [116] . Moreover, in studies of EBV-specific T cells derived from healthy donors, polyfunctional T cells were more resistant to Gal-1-mediated inhibitory effects than EBV-specific CD8 + T cells that were not polyfunctional (secreted a single cytokine) [113] . EBV-specific CD8 + T cells were exquisitely sensitive to recombinant Gal-1-induced apoptosis, with apoptosis abrogated by the introduction of a Gal-1-neutralizing antibody [117] . This suggests that Gal-1 is an important negative regulator of the cytotoxic T lymphocyte (CTL) response in EBV antigen-associated HL tumour immunity, although CTLs specific for lytic (nonlatency) associated antigens were not impaired by Gal-1 [72, 113] .
CTLs are important for the control of HSV-1 infection. This is highlighted by the numerous mechanisms HSV-1 has evolved to evade the CTL response [118] . As Gal-1 expression and secretion is upregulated in HSV-1 infection, Gal-1 suppression of CTL responses to HSV-1 has been investigated. Treatment of anti-CD3-stimulated T cells with Gal-1-containing media derived from HSV-1 infected cell cultures caused apoptosis. The pro-apoptotic activity of the supernatants was abrogated in part by a galectin-specific inhibitor (thiodigalactoside) or an anti-Gal-1 blocking antibody [74] . This suggests that Gal-1 secretion by infected cells could be a mechanism by which HSV-1 impedes the CTL response.
Interestingly, the suppression of anti-viral T cells could also contribute to the reduction of morbidity associated with ocular HSV-1 infection, where the infiltrating immune response is a major contributor to tissue damage. In a murine model of ocular HSV-1 infection, Gal-1 was shown to have an immunosuppressive role that improved lesion outcomes in these mice [119] . Gal-1 treatment decreased the influx of effector CD4 + T cells and innate cells, including neutrophils. There was also a reduction in cytokine production (IFN-g and IL-17) by infiltrating CD4 + T cells [119] . Importantly, Gal-1 treatment did not delay clearance of the virus from infected eyes [119] . Thus, the net effect of Gal-1 may be T cell-suppressive but still beneficial to the host.
The investigation of Gal-9 regulation of the immune response to viral infection has focused on the T cell-suppressive signalling induced by Gal-9 binding to the T cell receptor, Tim-3. The observation that a number of chronic viral infections, including HIV-1 [120] , HCV [105, [121] [122] [123] , HBV [93, 106, 124] , HAV [101] and EBV [125] , upregulate Tim-3 expression and/or the frequency on effector T cells prompted further investigation of the role of this receptor ligand interaction in anti-viral immunity. So far it is not clear if Tim-3 is upregulated during chronic HCMV infection [93, 120, 121] .
Investigation of Gal-9 activity during EBV infection determined that Gal-9 treatment reduced the proliferation of PBMC-derived T-cells [126] . In HCV infection, Gal-9 treatment expanded immune suppressive T-reg cells [102] , with the addition of Gal-9 to CD4 + T cells in vitro being sufficient to convert them into Foxp3+ T regs [96] . Similarly, during chronic HBV infection the memory T-reg population was increased, correlating with increased serum Gal-9. Treatment with Gal-9 was able to expand this memory Treg population in vitro in a Tim-3-dependent manner [127] . Furthermore, a unique T cell population of functionally exhausted (Tim-3+PD-1+) Th17 and Th2 cells was identified. These T cells had poor effector function and reduced proliferative capacity, which could be recalled, stopping Gal-9-Tim-3 interactions with a Tim-3 blocking antibody [93] . Gal-9 also induced apoptosis in HCV-specific CTL clones, driven by caspase-8-dependent activation-induced cell death [102, 104] . Gal-9 can also drive apoptosis of CD4 + EBV-specific T cells [125] . Thus, in these chronic viral infections, induction of Gal-9 has been associated with the suppression of anti-viral T cell responses, although it is yet to be determined whether Gal-9 is also able to interact with virions and/or target cells to modulate infection with these viruses directly.
Interestingly, during HIV-1 infection, Gal-9 is also associated with T-reg-mediated suppression of CD8 + CTL proliferation, but this was targeted to non-protective HIV-1-specific T cells [128] . A subset of HIV-1 patients can be designated as long-term non-progressors. These are chronically infected patients with low viral loads and sustained CD4 + T cell counts. Expression of HLA-B*27 and HLA-B*57 in long-term non-progressors correlated with longer AIDSfree survival. HLA-B*27-or HLA-B*57-restricted CD8 + CTLs did not express increased Tim-3 and thus were resistant to Gal-9-induced apoptosis [128] . Therefore, Gal-9-Tim-3 interactions selected for protective CTLs while suppressing non-protective CTL populations. The protective T cells with the HLA-B*27 or HLA-B*57 allele restriction were associated with the resolution of other chronic viral infections (HCV) [129] , and the phenotype of reduced susceptibility to suppression was confirmed for HLA-B*27 or HLA-B*57 allele-restricted CD8 + T cells produced against HSV-2 and EBV [128] .
The ability of Gal-9 to suppress T cell responses to infection can also be virus-specific, and this is highlighted by comparing the regulation of T cell responses to two acute respiratory viral infections, IAV and respiratory syncytial virus (RSV). Tim-3 expression on CD8 + T cells and the subsequent Gal-9-mediated immune regulation was investigated in a murine model of IAV infection. Increased frequencies of Tim-3-expressing CD8 + and CD4 + T cells occurred following the infection and ex vivo treatment of CD8 + T cells derived from infected mice with Gal-9-increased apoptosis. Thus, this mouse model indicated that Gal-9-Tim-3 interactions during IAV infection limited the response of the CD8 + T cells [91] . In contrast, RSV infection of mice resulted in decreased Tim-3 expression on both PBMC-and lung-derived T cells compared to non-infected mice. Interestingly, increased expression of Gal-9 led to reduced apoptosis of CD8 + T cells, the main cell type involved in killing RSV-infected cells and reducing viral load [130] . Gal-9 expression during RSV infection also reduced Th17 cells but not Th1 or Th2 cells, and increased T-reg cell frequency compared to RSV infection alone. Furthermore, IFN-g levels were unaffected by increased expression of Gal-9 [131] . Thus, Gal-9 can have bidirectional regulatory properties, and potentially Tim-3-independent mechanisms to promote T cell function.
CTLs are a critical component of the immune response to many viruses, but they also have the ability to damage host tissue. For this reason, the activity of CTLs is tightly regulated by many receptor-ligand interactions. Depletion or suppression of activated CTLs can be an important part of the resolution of pathology associated with infection [132] [133] [134] . A major complication of HSV-1 infection, as mentioned above, is blindness associated with ocular infection and associated immunopathology orchestrated by T cells [135, 136] . During HSV-1 ocular infections Gal-9 can act to induce apoptosis in pathogenic CD4
+ T cells and induce Treg populations [137] . Gal-9-Tim-3 interactions downregulate the T cell response, but as an uncontrolled T cell response is associated with immunopathology, Gal-9 treatment has been advocated as a potential treatment strategy for reducing lesion severity [137] . The trade-off is that Gal-9 downregulates protective anti-viral CD8 + T cells responses' to HSV-1 [138] . Gal-9KO mice developed greater frequencies of virus-specific CD8 + T cells, with a higher proportion of polyfunctional cells [98, 139] . CD8 + T cells from Gal-9KO mice also had enhanced proliferation, and increased CD107a expression compared to WT mice. In addition, reactivation of HSV-1 from latently infected trigeminal ganglia was attributed to Gal-9-mediated loss of CD8 + T cells [98] . Thus, this localized ocular activity of Gal-9 could be advantageous in reducing immunopathology associated with HSV-1 infection, but systemic Gal-9 could act to supress the protective T cell response, even to the point to inducing reactivation.
Impact of galectins on NK cells during virus infection
In addition to CTLs, NK cells present a significant component of the anti-viral immune response. NK cells constitutively express high levels of Tim-3, and can be activated by various cytokines [140] [141] [142] . Tim-3 is associated with exhausted and dysfunctional T cells, whereas on NK cells, Tim-3 expression is a marker of maturation or fully functional NK cells. Interactions between Gal-9 and Tim-3 on the surface of NK cells can be activating, resulting in enhanced IFN-g production, or inhibitory, reducing the cytotoxic capacity of NK cells, and appear to be highly context-dependent [140, 141] . Tim-3 expression was significantly reduced on NK cells in HIV-1-infected patients compared to healthy individuals [43] . Incubation of NK cells with Gal-9 triggered the activation of NK cells, measured by increased CD107a surface expression, as well as decreased Tim-3 expression, but was not associated with a significant increase in soluble IFN-g [43] . During chronic HBV infection Tim-3 was upregulated on NK cells, and blocking of Tim-3 resulted in enhanced cytotoxic activity and IFN-g production in response to target cells, with Gal-9 expression also being associated with protection from NK cell cytoxicity [143] . This suggests that Gal-9-Tim-3 interactions are likely to play an inhibitory role in NK cell function in chronic HBV infection [143] . In addition, in MCMV infection, the proportion of NK cells that spontaneously produced IFN-g was higher in Gal-9KO mice [144] . Therefore, the exposure of NK cells to Gal-9 early but not late in infection may be beneficial for the control of viral infection, and this is likely to be dependent on Tim-3 expression. Overall, however, the role of Gal-9, in combination with Tim-3 or yet to be identified receptors, in NK cell regulation remains to be fully elucidated.
Impact of galectins on other innate immune cells during virus infection
The infiltration of innate immune cells forms the first line of cellular defence against invading pathogens. Regulation of this response is required to prevent excessive damage to host tissue. Pathogenesis resulting from H5N1 IAV is at least in part due to the excessive virus-induced inflammatory response [145] . Macrophages, in particular, have been identified as major contributors to immunopathology and tissue injury associated with H1N1 IAV infection of the lungs [79, 146, 147] . A mouse model of H1N1 IAV infection determined that Gal-3 was upregulated in response to infection [79] . Compared to Gal-3KO mice, wild-type mice exhibited more severe airway inflammation, including greater frequencies of infiltrating neutrophils and greater IL-1b production. However, no differences in markers of tissue injury were evident and Gal-3KO did not affect in vivo viral replication of H1N1 early during infection (first 5 days), or the survival rates of infected mice, when compared to infected wild-type mice. Conversely, Chen et al. suggest that Gal-3 promotes H1N1-induced inflammation via the promotion of NRLP3 inflammasome assembly, resulting in enhanced IL-1b production [79] . Thus, Gal-3, though pro-inflammatory, appears to contribute to immunopathology associated with IAV infection [79] . This suggests that Gal-3 is acting as a positive immune regulator via the induction of IL-1b, a proinflammatory cytokine, which itself induces the expression of other pro-inflammatory mediators, cytokines and chemokines that trigger leukocyte production [148] . An anti-viral role for Gal-3 is supported by the upregulation of anti-viral genes during Gal-3 treatment of IAV-infected cells in vitro [59] . This corresponded with reduced cytopathic effect and reduced viral yield, indicating that Gal-3 may play a productive role in the anti-viral response.
It is important to consider other innate immune cells ,as they are early cellular responders to infection and shape the resulting immune response via signalling and downstream activation of effector cells. During DENV infection of DCs, siRNA knockdown of Gal-9 resulted in diminished migration potential for DENV-infected DCs, in vitro [89] . The effect of Gal-9 on DC migration was Tim-3-independent [89] , but whether the outcome of this reduced migration is suppression of viral dissemination or reduction of DCmediated immune activation remains to be determined. In HCV infection, Gal-9 treatment of peripheral and liverderived mononuclear cells induced pro-inflammatory mediator expression, including TNF-a, IL-1b and IFN-g. In contrast, PBMCs were induced to express the antiinflammatory cytokines IL-4, IL-10 and IL-13 by Gal-9 [102] . The net effect of this bidirectional induction of both pro-and anti-inflammatory mediators remains to be determined.
In addition to the regulation of immune cells, galectins may also act as potential receptors for pathogen-associated molecular patterns (PAMPs) during microbial infections [14] . Danger signals form part of the pathogen-sensing mechanism, and galectins can recognize microbial-induced membrane damage. In this respect, abnormal exposure of intra-luminal glycans can be sensed by Gal-8 as a virusassociated damage signal [149] . In adenovirus and picornavirus infection Gal-8 can be an essential restriction factor [150, 151] . Gal-8 recruitment towards adenovirus-ruptured membranes marks virus-associated membranes for autophagosomal degradation [150] . Thus, Gal-8 can contribute to cellular sensing and viral degradation. The identification of Gal-8 as cellular sensor of viral infection has only very recently emerged and this could be an important new avenue of research for the field of galectin-virus interactions.
CONCLUSIONS AND PERSPECTIVES
In the context of viral infection, galectins have been demonstrated to have altered expression, they can be involved in direct interactions with virion or target cells, and they can regulate the immune response to viral infection. Thus, galectins may function as both markers for and regulators of virus-host interactions.
Galectins are clearly able to regulate viral infection and spread. In a context-dependent manner, galectins can interact with glycans of both viruses and/or target cells to promote viral attachment and entry, inhibit attachment or fusion, abrogate viral spread, regulate the release of viral progeny and influence the reactivation of latent viral infections. In most cases, the glycan ligands that facilitate individual galectin-virus interactions remain largely unknown, so it will be important to address key issues such as glycan variability, for example that resulting from both cell-type-specific glycosylation patterns and heterogeneity in viral glycosylation between virus serotypes and strains. Better characterization of carbohydrate moieties on viral glycoproteins may facilitate more accurate predictions regarding the potential pro-or anti-viral activity of specific galectins bound to defined glycans. Future research is required to better characterize viral glycans and the mechanisms by which they interact with cellular receptors in both the presence and absence of galectins. Improvements in biological structural analysis techniques, including cryo-electron microscopy, are likely to play a significant role in moving this aspect of the field forward, facilitating greater mechanistic insights into galectin-mediated control of viral infection.
Galectins are commonly regulated during viral infection. Predominantly infection results in the upregulation of the expression of one or more galectin and often results in systemic upregulation. Galectins, like many cytokines, can have a differential effect on immune responses. This depends on many different factors, including their dimerization or oligomerization state and their concentration, as well as the activation and differentiation state of the immune cells that express galectin receptors. The importance of galectins as innate and adaptive immune regulators has been extensively described. In the context of viral infections, galectins mainly function to limit anti-viral T cell responses. The research conducted to date may not encompass the full potential of galectin-mediated immune regulation during viral infection. Gal-9, for example, has only been investigated for its Tim-3-dependent regulation of T cell survival and functionality. A number of T cell receptors for Gal-9 have been identified to date, but their roles in T cell regulation remain to be elucidated. Galectin binding of T cell receptors is also dependent on the activation state of the cells. Therefore, it will be important to determine how galectin-receptor interactions impact on virus-specific T cell responses at different stages of the antiviral immune response. Assessment of the regulation resulting from galectin interactions with their receptors will help to inform us about the overall contribution of galectins as pro-and/or anti-viral lectins. Furthermore, many cells of the immune systems are involved in responding to viral pathogens. A number of key cell types involved in responding to and/or shaping the immune response to infection remain to be studied. Specifically, B cells, monocytes and DCs are key immune cells that have been shown to regulated by galectins [108, 109, 111, 112] , but the significance of this during viral infection presents an avenue for future research.
The overall contribution of different galectins individually and in combination during viral infections will also be an important area for further work. For example, in HIV-1 infection, Gal-1 seems to play a role in promoting viral infection of T cells and macrophages, but whether Gal-1 expression is elevated during HIV-1 infection in patients and is critically involved in determining the outcome is unknown. In the context of viral infections, where many simultaneous processes take place to facilitate a complex network of host-virus interaction, signalling and effector mechanisms, it is important to establish whether the net effect of different galectins' activity benefits the host or the virus.
The discovery that several galectins are directly involved in virus recognition has opened up new avenues of research aimed at disrupting their roles in virus-host interactions. However, before galectin-based therapies can be embraced, greater understanding of the mechanisms involved in the functions of these proteins is necessary. This includes studies of the compensatory, unique or synergistic regulatory effects of individual galectins in regulating virus-host interactions and in regulating immune responses. A comparative analysis of the pro-or anti-viral effects of galectin-specific inhibitors, such as blocking antibodies, synthetic glycolmimetics or natural polysaccharides, in modulating the proand anti-viral activities of galectins is also needed. Roles for galectins and their glycan partners have been identified in a wide range of biological processes, and as such they have been proposed as potential therapeutic targets or agents in limiting autoimmunity, preventing allograft rejection and enhancing anti-tumour responses. Based on their broad activity and diverse potential therapeutic applications, it will be as important to understand the potential benefits or sideeffects associated with abrogating galectin function during viral infections.
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